The US Food and Drug Administration (FDA) has added new data to United Kingdom-based Circassia Pharmaceuticals' TUDORZA PRESSAIR (aclidinium bromide inhalation powder) prescribing information, it was reported yesterday.

The prescribing information includes information data from the ASCENT trial showing that TUDORZA PRESSAIR decreases exacerbations in chronic obstructive pulmonary disease (COPD) and does not increase major adverse cardiovascular events in COPD patients with cardiovascular disease and/or significant cardiovascular risk factors.

The product is a prescription medicine used two times a day for the maintenance treatment of COPD. It is not a rescue medicine and should not be used for treating sudden breathing problems.